Introduction
============

The apoptotic process, in which cells are actively eliminated by a programmed pathway, is increased in sepsis. Extrinsic and intrinsic apoptotic death cell pathways activate caspase-3, which leads to cell apoptosis. Cytokeratin 18 (CK-18), a protein present in most epithelial and parenchymal cells, is cleaved by the action of caspases and released into the blood as caspase-cleaved CK (CCCK)-18 during apoptotic death. The novel objectives of this study were to determine whether there are associations between serum caspase-3 levels, serum CK-18 levels and mortality in septic patients.

Methods
=======

A prospective, multicenter, observational study in six Spanish ICUs, including 216 patients with severe sepsis. We collected blood samples at the severe sepsis diagnosis moment to determine serum levels of caspase-3 (to assess the main executor of apoptosis) and CCCK18 (to assess the apoptosis level). The endpoint was 30-day mortality.

Results
=======

We found that nonsurvivor (*n*= 76) in comparison with survivor (*n*= 140) septic patients showed higher serum levels of caspase-3 (0.41 ng/ml (0.14 to 0.52) vs. 0.11 ng/ml (0.10 to 0.25); *P*\< 0.001) and CCCK18 (448 (310 to 723) vs. 319 (236 to 445); *P*\< 0.001). Multiple logistic regression showed that serum caspase-3 levels \>0.25 ng/ml were associated with mortality at 30 days (odds ratio = 6.51; 95% confidence interval = 3.32 to 12.77; *P*\< 0.001), controlling for SOFA score and age. Kaplan-Meier survival analysis showed a higher risk of death in septic patients with serum caspase-3 levels \>0.25 ng/ml than in patients with lower levels (hazard ratio = 3.80; 95% CI = 2.35 to 6.15; *P*\< 0.001). We found a positive association between serum levels of caspase-3 and CCCK-18 (ρ = 0.32; *P*\< 0.001).

Conclusion
==========

The novel findings of our study were that there is an association between serum caspase-3 levels, serum CK-18 levels and mortality in septic patients. There has been reported decreased apoptosis and increased survival in septic rats with the administration of caspase inhibitors; thus, it may be interesting to explore those agents in septic patients.
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